-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma Multiforme...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium (186Re) Obisbemeda in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Squamous Cell Carcinoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Leptomeningeal...
-
Sector Analysis
NewOsteoporosis Epidemiology Analysis and Forecast to 2033
Osteoporosis Report Overview In the 7MM, there were 20,291,551 diagnosed prevalent cases of osteoporosis in 2023. The diagnosed prevalent cases of osteoporosis will register an AGR of more than 1% during 2023-2033. Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person’s bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STR-324 in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STR-324 in Post-Operative Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STR-324 in Post-Operative Pain Drug Details: STR-324 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Butylphthalide in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Butylphthalide in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Butylphthalide in Acute Ischemic Stroke Drug Details: Butylphthalide (n-butylphthalide) is...
-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-10508 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-10508 in Major Depressive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-10508 in Major Depressive Disorder Drug Details: XW-10508 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASN-90 in Progressive Supranuclear Palsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASN-90 in Progressive Supranuclear Palsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASN-90 in Progressive Supranuclear Palsy Drug Details: ASN-90 is under...